November is the worst month for pedestrian collisions. Here's why ...

Jefferies has initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT) at buy saying its Duchenne muscular dystrophy franchise represents a $4B+ opportunity, as well as a strong pipeline and ...

In the latest quarter, 16 analysts provided ratings for Sarepta Therapeutics (NASDAQ:SRPT), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of ...

Sarepta Therapeutics sells one of the most expensive ... drug in the future based on the incident population, meaning new ...

STAT+ subscribers can sign up here to get it delivered to their inbox. Sarepta Therapeutics CEO Doug Ingram is upset about the company’s slumping stock price. Investors who have interacted ...

In June, the FDA expanded its approval of Sarepta Therapeutics’ Elevidys gene therapy for Duchenne muscular dystrophy to all patients ages four and older. The one-time treatment (which costs $3. ...

New York State Teachers Retirement System owned 0.08% of Sarepta Therapeutics worth $9,763,000 as of its most recent SEC filing. Other hedge funds have also added to or reduced their stakes in the ...

Analyst Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price target at $200.00. Uy Ear has given his Buy rating due to a ...

Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $200.00. Michael Ulz has given his Buy rating due to a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...